Literature DB >> 3318891

Bone resorption and turnover in health and disease.

G R Mundy1.   

Abstract

Excessive bone loss is a common cause of disability and presents a major public health problem in western societies. The most common cause is age-related bone loss and osteoporosis, but other common diseases associated with increased bone resorption include malignant disease, primary hyperparathyroidism, and Paget's disease. Despite the frequency of these disorders and the suffering they cause, their pathophysiology still remains obscure. However, recent advances in techniques in bone cell biology are now providing new insights into the pathogenesis and treatment of diseases associated with increased bone resorption. These advances have been paralleled by improvements in techniques for non-invasive assessment of bone status in patients with the common metabolic bone diseases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3318891

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  14 in total

1.  Human pharmacokinetics of orally administered strontium.

Authors:  O R Leeuwenkamp; W J van der Vijgh; B C Hüsken; P Lips; J C Netelenbos
Journal:  Calcif Tissue Int       Date:  1990-09       Impact factor: 4.333

2.  Neurophysiology of Cancer Pain: From the Laboratory to the Clinic.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

Review 3.  Strategies for management of prostate cancer-related bone pain.

Authors:  R C Pelger; V Soerdjbalie-Maikoe; N A Hamdy
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo.

Authors:  G Golomb; A Schlossman; H Saadeh; M Levi; J M Van Gelder; E Breuer
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

5.  Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.

Authors:  Julie R Gralow; William E Barlow; Alexander H G Paterson; Jieling L M'iao; Danika L Lew; Alison T Stopeck; Daniel F Hayes; Dawn L Hershman; Mark M Schubert; Mark Clemons; Catherine H Van Poznak; Elizabeth C Dees; James N Ingle; Carla I Falkson; Anthony D Elias; Michael J Messino; Jeffrey H Margolis; Shaker R Dakhil; Helen K Chew; Kim Z Dammann; Jeffrey S Abrams; Robert B Livingston; Gabriel N Hortobagyi
Journal:  J Natl Cancer Inst       Date:  2020-07-01       Impact factor: 13.506

Review 6.  The role of bisphosphonates as adjuvant therapy for breast cancer.

Authors:  J R Gralow
Journal:  Curr Oncol Rep       Date:  2001-11       Impact factor: 5.075

Review 7.  Clodronate in hypercalcemia of malignancy.

Authors:  J P Bonjour; R Rizzoli
Journal:  Calcif Tissue Int       Date:  1990       Impact factor: 4.333

8.  A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis.

Authors:  Ma Scheper; R Chaisuparat; Kj Cullen; Tf Meiller
Journal:  Fibrogenesis Tissue Repair       Date:  2010-04-01

9.  Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis.

Authors:  Mark A Scheper; Ashraf Badros; Risa Chaisuparat; Kevin J Cullen; Timothy F Meiller
Journal:  Br J Haematol       Date:  2008-11-20       Impact factor: 6.998

Review 10.  Cellular and molecular toxicity of lead in bone.

Authors:  J G Pounds; G J Long; J F Rosen
Journal:  Environ Health Perspect       Date:  1991-02       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.